Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Clinical Development Of PD-1 In Advanced Melanoma

R. Munhoz, M. Postow
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract The development of new treatment options has dramatically improved the landscape for patients with advanced melanoma. Part of these advances emerged through the identification of the importance of factors that regulate the immune system, including proteins that negatively modulate T cell–mediated responses termed “immune checkpoints.” Indeed, blockade of the cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint served as a proof of principle that the manipulation of these molecules could induce robust anticancer effects, yet limited to a small percentage of patients. Targeting a distinct checkpoint, the PD-1 yielded improved outcomes and reduced toxicity compared with CTLA-4 blockade and, in separate studies, chemotherapy. More recently, combined CTLA-4/PD-1 blockade was shown to result in higher response rates, while accompanied by increased toxicity. In this article, we review the clinical development of anti–PD-1 monotherapy and combinations that may expand the benefit of immunotherapy for patients with advanced melanoma.
This paper references
10.1200/JCO.2016.34.15_SUPPL.9513
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
A. Daud (2016)
10.1126/SCIENCE.291.5502.319
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
10.1016/S1470-2045(16)30366-7
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F. S. Hodi (2016)
10.1056/NEJMoa1412690
Improved overall survival in melanoma with combined dabrafenib and trametinib.
C. Robert (2015)
10.1016/S1470-2045(17)30428-X
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
G. Long (2017)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC)
GV Long (2018)
10.1200/JCO.2017.73.2289
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
D. Schadendorf (2017)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1016/S1470-2045(17)30231-0
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
P. Ascierto (2017)
Immune Checkpoint Blockade in Cancer Therapy
J. Allison (2008)
10.1016/S1470-2045(15)00083-2
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1038/nrclinonc.2017.43
Targeted agents and immunotherapies: optimizing outcomes in melanoma
J. Luke (2017)
10.1016/S1470-2045(16)30122-X
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
P. Ascierto (2016)
10.1200/JCO.2017.35.15_SUPPL.9520
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
P. Ascierto (2017)
10.1200/JCO.2014.32.15_SUPPL.3010
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Geoffrey T. Gibney (2014)
10.1200/JCO.2017.35.15_SUPPL.3033
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
H. Burris (2017)
10.1016/S1470-2045(16)30126-7
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
J. Weber (2016)
10.1200/JCO.2015.33.15_SUPPL.3012
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
I. Puzanov (2015)
10.1093/ANNONC/MDW379.06
Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
Tara C. Gangadhar (2016)
10.1200/JCO.2016.34.15_SUPPL.3075
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
Y. Zakharia (2016)
Final OS analysis for KEYNOTE-002: pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma
O Hamid (2016)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1200/JCO.2017.35.15_SUPPL.9507
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
H. Tawbi (2017)
10.1200/JCO.2017.35.15_SUPPL.3012
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
O. Hamid (2017)
10.1056/NEJMoa1504030
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1200/JCO.2016.71.8023
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
J. Larkin (2018)
10.1200/JCO.2014.56.2736
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
10.1200/JCO.2014.56.6018
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
M. Maio (2015)
10.1016/S1470-2045(15)70076-8
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1158/1538-7445.AM2017-CT075
Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)
J. Larkin (2017)
10.1038/nature10673
Cancer immunotherapy comes of age
I. Mellman (2011)
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1200/JCO.2017.35.15_SUPPL.3063
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
R. Sullivan (2017)
10.1093/INTIMM/8.5.765
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Y. Agata (1996)
10.1056/NEJMoa1414428
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
10.1038/nri3405
Molecular mechanisms of T cell co-stimulation and co-inhibition
L. Chen (2013)
10.1200/JCO.2014.32.15_SUPPL.9011
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
G. Long (2014)
10.1001/jama.2016.4059
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
A. Ribas (2016)
10.1200/JCO.2017.35.15_SUPPL.104
Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.
L. Siu (2017)
10.1200/JCO.2016.34.15_SUPPL.9503
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
C. Robert (2016)
10.1056/NEJMoa1503093
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.1186/s40425-015-0094-9
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Y. Moon (2015)
10.1016/S1470-2045(12)70090-6
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
K. Margolin (2012)
10.1016/S0140-6736(17)31601-X
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J. Schachter (2017)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1200/JCO.2017.35.15_SUPPL.9504
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
C. Robert (2017)
10.1200/JCO.2017.35.15_SUPPL.3003
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
R. Perez (2017)
10.1200/JCO.2017.35.15_SUPPL.3007
Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.
R. Sanborn (2017)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)



This paper is referenced by
10.1158/2326-6066.CIR-18-0182
Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8+ T Cells
K. Hurst (2019)
10.1111/cup.13768
Non‐human‐papillomavirus‐related malignancies of the vulva: A clinicopathological study
Karina Furlan (2020)
10.5603/OCP.2020.0004
Summary of immunotherapy efficacy ordered in accordance with drug reimbursement program in melanoma patients
A. Czarnecka (2020)
10.1002/bies.201800079
Missed Druggable Cancer Hallmark: Cancer–Stroma Symbiotic Crosstalk as Paradigm and Hypothesis for Cancer Therapy
E. Sverdlov (2018)
10.1073/pnas.2015343117
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Silke Eisinger (2020)
10.3389/fimmu.2020.01112
The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
Janne Tegder Martinsen (2020)
10.3389/fonc.2020.596493
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
Z. Lin (2020)
10.7150/thno.42986
The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities
M. Alame (2020)
10.1080/08923973.2020.1837865
Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target
Ahmad-Reza Mahmoudi (2020)
10.1134/S1022795418120025
Emerging Potential of Cancer Therapy—Binary Direct Interactions of Cancer and Stromal Cells
I. Alekseenko (2018)
10.3322/caac.21630
An update on the immune landscape in lung and head and neck cancers
J. Carlisle (2020)
10.1016/j.wneu.2019.02.212
Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
D. Lin (2019)
10.1101/810028
The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities
M. Alame (2019)
10.1002/bies.202000024
Why the Outcome of Anti‐Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers
J. H. Wang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar